AR015500A1 - 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS. - Google Patents
11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.Info
- Publication number
- AR015500A1 AR015500A1 ARP980106471A ARP980106471A AR015500A1 AR 015500 A1 AR015500 A1 AR 015500A1 AR P980106471 A ARP980106471 A AR P980106471A AR P980106471 A ARP980106471 A AR P980106471A AR 015500 A1 AR015500 A1 AR 015500A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkenyl
- branched
- beta
- alpha
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 8
- 125000003342 alkenyl group Chemical group 0.000 abstract 6
- 125000000304 alkynyl group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
11 beta-halogeno-estratrienos sustituidos en 7 alfa, de formula I en donde R3 representa un átomo de hidrogeno, un resto de hidrocarburo con hasta 8 átomosde carbono o un resto de la subformula R3 - C(O)-, donde R3 representa un átomo de hidrogeno oun resto de hidrocarburo con hasta 8 átomos de carbono o unresto fenilo, R7 representa un resto con la formula -A-B-Z-R20, donde A figura un enlace directo o un resto bencilideno, donde el grupo metileno está enlazadoal átomo de carbono 7 delesteroi de, o un resto fenilo, Bfigura para un grupo alquileno, alquenilo o alquinilo con 3 a 14 átomos de carbono, lineal oramificado; y Z figura para un grupo -NR21, y R21 para un grupo alquilo C1-3, donde , entonces R20 representa un átomo dehidrogeno, u n grupo alquilo,alquenilo o alquinilo con hasta 10 átomos de carbono, lineal o ramificado, o uno de los agrupamientos D-CnF2n + 1, donde D representa un grupo alquileno,alquenilo o alquinilo con hasta 8 átomos de carbono, lineal oramificado, y n un numero entero de 1 a 8, L-CH = CF - CpF2p + 1, donde L representa un grupoalquileno, alquenilo o alquinilo con C2-7, lineal o ramificado, y representa un numero entero de 2 a 7, D-O-(CH2)-q-arilo, donde D representa lo mismo queloya indicado, q a 0, 1, 2 o 3 y arilo figura para un resto fenilo o 1- o 2-naftilo, en casos dados, sustituido una o dos veces, o un resto heteroarilo,D-O-(CH2)r-CnF2n + 1, donde D y n representan lo mismo que lo ya indicado, y r figura para unnumero entero de 1 a 5, o R20 y R21, junto con el nitrogeno alque están unidos, forman un heterociclo saturado o insaturado con 5 o 6 miembros de cadena que, en casos dados, contiene uno o dos heteroátomos seleccionadosentre nitrogeno, oxígeno yazufre y en casos dados, es ta sustituido o Z figura para -SOx- y x para 0, 1 o 2, donde, entonces, R20 representa un grupo alquilo,alquenilo o alquinilo con hasta 10 átomos de carbono, lineal o ramificado, o uno de los agrupamientos D-CnF2n + 1,donde D representa un grupo alq uileno,alquenilo o alquinilo con hasta 8 átomos de carbono, lineal o ramificado, y n un numero entero de 1 a 8, L - CH = CF - CpF2p + 1, donde L representa un
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1997158390 DE19758390A1 (de) | 1997-12-23 | 1997-12-23 | 11ß-Halogen-7alpha-substituierte-Estratriene, Verfahren zur Herstellung pharmazeutischer Präparate, die diese 11ß-Halogen-7alpha-substituierte Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE1998106357 DE19806357A1 (de) | 1998-02-10 | 1998-02-10 | 11beta-Halogen-7alpha-substituierte-Estratriene, Verfahren zur Herstellung pharmazeutischer Präparate, die diese 11beta-Halogen-7alpha-substituierte Estratriene enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015500A1 true AR015500A1 (es) | 2001-05-02 |
Family
ID=26042916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106471A AR015500A1 (es) | 1997-12-23 | 1998-12-18 | 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6780855B2 (es) |
| EP (1) | EP1042355B1 (es) |
| JP (1) | JP2001527088A (es) |
| KR (1) | KR20010024806A (es) |
| CN (1) | CN1131235C (es) |
| AR (1) | AR015500A1 (es) |
| AT (1) | ATE232543T1 (es) |
| AU (1) | AU750801B2 (es) |
| BG (1) | BG104553A (es) |
| BR (1) | BR9814416A (es) |
| CA (1) | CA2316444A1 (es) |
| DE (1) | DE59807213D1 (es) |
| DK (1) | DK1042355T3 (es) |
| EA (1) | EA002623B1 (es) |
| EE (1) | EE200000380A (es) |
| ES (1) | ES2191371T3 (es) |
| HU (1) | HUP0100568A3 (es) |
| ID (1) | ID26207A (es) |
| IL (1) | IL136938A0 (es) |
| IS (1) | IS5526A (es) |
| NO (1) | NO20003286L (es) |
| NZ (1) | NZ505348A (es) |
| PE (1) | PE20000129A1 (es) |
| PL (1) | PL341299A1 (es) |
| SK (1) | SK9442000A3 (es) |
| TR (1) | TR200001973T2 (es) |
| WO (1) | WO1999033855A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ299945B6 (cs) * | 2000-10-18 | 2008-12-29 | Schering Aktiengesellschaft | Lécivo obsahující 17alfa-fluoralkylsteroid pro lécení karcinomu prsu rezistentního vuci steroidum |
| AU2006202187B2 (en) * | 2001-11-27 | 2008-11-06 | Bayer Schering Pharma Aktiengesellschaft | 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations |
| DE10159217A1 (de) | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| EP1675843A1 (en) * | 2003-10-14 | 2006-07-05 | Council of Scientific and Industrial Research | (3r, 4r) -trans-3,4-diarylchroman derivatives with estrogenic activity |
| ATE482966T1 (de) * | 2004-07-27 | 2010-10-15 | Sicor Inc | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide |
| CN101312944B (zh) | 2005-11-22 | 2013-03-06 | 住友化学株式会社 | 有机硫化合物及其作为节肢动物杀灭剂的应用 |
| DE102007023614A1 (de) | 2007-05-21 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| DE102007049630A1 (de) | 2007-10-11 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| JP5298631B2 (ja) | 2007-05-18 | 2013-09-25 | 住友化学株式会社 | 有機硫黄化合物及びその有害節足動物防除用途 |
| JP2009001551A (ja) | 2007-05-18 | 2009-01-08 | Sumitomo Chemical Co Ltd | 有機硫黄化合物及びその有害節足動物防除用途 |
| TW200904329A (en) | 2007-05-18 | 2009-02-01 | Sumitomo Chemical Co | Organic sulfur compound and its use for controlling harmful arthropod |
| DE102007032800A1 (de) | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP2033948A1 (en) * | 2007-08-30 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | Process for preparing Estrogen-antagonistic 11beta-Fluoro-17alpha-alkylestra-1,3,5 (10)-triene-3, 17-diols having a 7alpha-(xi-Alkylamino-omega-perfluoroalkyl)alkyl side chain and alpha-Alkyl(amino)-omega-perfluoro(alkyl)alkanes and processes for their preparation |
| NZ585389A (en) | 2007-10-16 | 2011-10-28 | Repros Therapeutics Inc | Trans-clomiphene for metabolic syndrome |
| EP2053055A1 (de) * | 2007-10-24 | 2009-04-29 | Bayer Schering Pharma Aktiengesellschaft | 11.beta.-Fluoro-3-acetoxyestra-3,5-dien-17-on und Verfahren zu seiner Herstellung |
| DE102007058747A1 (de) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP2070942A1 (de) | 2007-12-13 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Aromatisierung von 19-Nor-androst-4-en-3-onen zu Estra-1,3,5(10)-trienen |
| EP2070909A1 (de) | 2007-12-15 | 2009-06-17 | Bayer Schering Pharma AG | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP2070941A1 (en) | 2007-12-14 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Stereoselective synthesis of selective estrogen receptor down-regulators |
| EP2258375A1 (de) | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratriene |
| DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010030538A1 (de) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| DE102011004899A1 (de) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102011087987A1 (de) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| ES2681023T3 (es) | 2012-02-29 | 2018-09-11 | Repros Therapeutics Inc. | Terapia de combinación para tratar el déficit de andrógenos |
| KR102198059B1 (ko) | 2013-04-11 | 2021-01-05 | 바이엘 파마 악티엔게젤샤프트 | 프로게스테론 수용체 길항제 투여 형태 |
| EP2987799B1 (en) * | 2013-04-18 | 2020-04-08 | Xi'an Libang Pharmaceutical Technology Co.,ltd. | Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof |
| CN104387435B (zh) * | 2014-12-10 | 2017-05-10 | 天津孚音生物科技发展有限公司 | 一种化合物及其制备方法与应用 |
| CN106146599A (zh) * | 2015-04-07 | 2016-11-23 | 江苏希迪制药有限公司 | 一种回收因亚砜构型比例不合格的氟维司群或其衍生物的方法 |
| US11633382B2 (en) | 2015-11-10 | 2023-04-25 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen |
| CN112778089B (zh) * | 2021-01-04 | 2023-09-05 | 万知科技股份有限公司 | 一种4,4,4-三氟-1-丁醇及其同系物的新合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3076829A (en) * | 1961-09-15 | 1963-02-05 | Schering Corp | Novel 9, 11-disubstituted estratriene derivatives |
| GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
| US5866560A (en) * | 1996-08-20 | 1999-02-02 | Schering Ag | 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents |
| DE19635525A1 (de) * | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
-
1998
- 1998-12-18 AR ARP980106471A patent/AR015500A1/es not_active Application Discontinuation
- 1998-12-18 PE PE1998001246A patent/PE20000129A1/es not_active Application Discontinuation
- 1998-12-23 AT AT98966410T patent/ATE232543T1/de not_active IP Right Cessation
- 1998-12-23 IL IL13693898A patent/IL136938A0/xx unknown
- 1998-12-23 NZ NZ505348A patent/NZ505348A/xx unknown
- 1998-12-23 WO PCT/EP1998/008470 patent/WO1999033855A1/de not_active Ceased
- 1998-12-23 TR TR2000/01973T patent/TR200001973T2/xx unknown
- 1998-12-23 ID IDW20001234A patent/ID26207A/id unknown
- 1998-12-23 DE DE59807213T patent/DE59807213D1/de not_active Expired - Fee Related
- 1998-12-23 PL PL98341299A patent/PL341299A1/xx unknown
- 1998-12-23 CN CN98812631A patent/CN1131235C/zh not_active Expired - Fee Related
- 1998-12-23 SK SK944-2000A patent/SK9442000A3/sk unknown
- 1998-12-23 EA EA200000711A patent/EA002623B1/ru not_active IP Right Cessation
- 1998-12-23 JP JP2000526531A patent/JP2001527088A/ja active Pending
- 1998-12-23 EP EP98966410A patent/EP1042355B1/de not_active Expired - Lifetime
- 1998-12-23 AU AU22763/99A patent/AU750801B2/en not_active Ceased
- 1998-12-23 HU HU0100568A patent/HUP0100568A3/hu unknown
- 1998-12-23 BR BR9814416-2A patent/BR9814416A/pt not_active IP Right Cessation
- 1998-12-23 DK DK98966410T patent/DK1042355T3/da active
- 1998-12-23 CA CA002316444A patent/CA2316444A1/en not_active Abandoned
- 1998-12-23 EE EEP200000380A patent/EE200000380A/xx unknown
- 1998-12-23 ES ES98966410T patent/ES2191371T3/es not_active Expired - Lifetime
- 1998-12-23 KR KR1020007006955A patent/KR20010024806A/ko not_active Withdrawn
- 1998-12-23 US US09/380,413 patent/US6780855B2/en not_active Expired - Fee Related
-
2000
- 2000-06-09 IS IS5526A patent/IS5526A/is unknown
- 2000-06-22 NO NO20003286A patent/NO20003286L/no not_active Application Discontinuation
- 2000-06-23 BG BG104553A patent/BG104553A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20003286D0 (no) | 2000-06-22 |
| NO20003286L (no) | 2000-08-23 |
| PL341299A1 (en) | 2001-04-09 |
| BG104553A (bg) | 2001-02-28 |
| AU750801B2 (en) | 2002-07-25 |
| EP1042355B1 (de) | 2003-02-12 |
| CN1131235C (zh) | 2003-12-17 |
| ID26207A (id) | 2000-12-07 |
| ES2191371T3 (es) | 2003-09-01 |
| EA002623B1 (ru) | 2002-06-27 |
| US20030069434A1 (en) | 2003-04-10 |
| PE20000129A1 (es) | 2000-03-11 |
| EE200000380A (et) | 2001-12-17 |
| DE59807213D1 (de) | 2003-03-20 |
| US6780855B2 (en) | 2004-08-24 |
| HUP0100568A2 (hu) | 2001-08-28 |
| AU2276399A (en) | 1999-07-19 |
| KR20010024806A (ko) | 2001-03-26 |
| WO1999033855A1 (de) | 1999-07-08 |
| SK9442000A3 (en) | 2001-04-09 |
| IL136938A0 (en) | 2001-06-14 |
| HUP0100568A3 (en) | 2002-01-28 |
| EP1042355A1 (de) | 2000-10-11 |
| CA2316444A1 (en) | 1999-07-08 |
| NZ505348A (en) | 2002-10-25 |
| BR9814416A (pt) | 2000-10-10 |
| ATE232543T1 (de) | 2003-02-15 |
| IS5526A (is) | 2000-06-09 |
| CN1286693A (zh) | 2001-03-07 |
| TR200001973T2 (tr) | 2001-01-22 |
| EA200000711A1 (ru) | 2001-02-26 |
| DK1042355T3 (da) | 2003-04-22 |
| JP2001527088A (ja) | 2001-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015500A1 (es) | 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS. | |
| UA41875C2 (uk) | Спосіб інгібування естрогензалежних пухлин з використанням стероїдних сульфатовмісних інгібіторів | |
| AR005357A1 (es) | Derivados de 14-o-carbamoil mutilina y sus sales utiles en el tratamiento de infecciones bacterianas, procedimiento para prepararlas, composicionesfarmaceuticas formuladas con dichos derivados y uso de los mismos para preparar dichas composiciones | |
| ES2130390T3 (es) | Taxanos substituidos con furilo o tienil carbonilo y composiciones farmaceuticas que los contienen. | |
| MX9205311A (es) | Nuevos taxanos substituidos y composiciones farmaceuticas que los contienen | |
| DK0419905T3 (da) | Quinonderivater og farmaceutisk anvendelse | |
| CO5050310A1 (es) | Composiciones desinfectantes y procesos para desinfectar superficies cesos para desinfectar superficies | |
| RU94031155A (ru) | Амидин - производные, способ их получения, их использование в качестве ингибиторов no - синтазы, фармсостав, способ лечения | |
| ES2102478T3 (es) | Complejos de vanadio, su preparacion y composiciones farmaceuticas que los contienen. | |
| FI954105A0 (fi) | Uusia 4-aminopyridiinejä, niiden valmistusmenetelmä sekä näitä yhdisteitä sisältäviä lääkkeitä | |
| ES2307337T3 (es) | Medicamentos peptidicos anti-angiogenicos. | |
| ATE234298T1 (de) | Zyklische etherverbindungen als natriumkanal- modulatoren | |
| DK0463945T3 (da) | Chalcon-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende derivaterne | |
| DK0409406T3 (da) | Arylsubstituerede aminderivater, der er anvendelige ved cancerterapi | |
| DK0779886T3 (da) | Dihydrobenzofuran og beslægtede forbindelser, der er anvendelige som antiinflammatoriske midler | |
| MX9302957A (es) | Compuestos de xantina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
| MX9301045A (es) | Procedimiento para preparar antagonistas receptores de fibrinogeno. | |
| ES471245A1 (es) | Un procedimiento para la preparacion de una composicion her-bicida a base de derivados de n'-fenil-n-metilurea | |
| ES2038846T3 (es) | Compuestos relacionados con la acetazolamida, procedimiento para su preparacion, y composicion farmaceutica que contiene los mismos. | |
| CO5080785A1 (es) | Derivados heterociclicos | |
| AR029618A1 (es) | Compuestos de amida , procedimientos para prepararlos, las composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos | |
| ES2057802T3 (es) | Nuevos derivados de 3-amino-cromano, procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| ES2069719T3 (es) | Nuevos derivados de tiofeno, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ATE9231T1 (de) | Polyamid-zusammensetzungen enthaltende glasfasern und eine ungesaettigte acrylverbindung. | |
| FR2658821B1 (fr) | Nouvelles propanamines, leurs proprietes pharmacologiques et leur application a des fins therapeutiques, notamment antidiarrheuiques. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |